Radioterapia y 5-fluorouracilo-cisplatino en el tratamiento del cáncer de cuello uterino de alto riesgo
Radiotherapy and 5-fluorouracil-cisplatin treatment for high-risk uterine cervical cancer
Barra lateral del artículo
PDF
FLIP
HTML
EPUB
XML
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Contenido principal del artículo
Resumen
Objetivo: evaluar la eficacia de la combinación de radioterapia y 5-fluorouracilo-cisplatino en el tratamiento del cáncer de cuello uterino de alto riesgo. Materiales y métodos: estudio retrospectivo en el que se revisaron los datos de pacientes tratadas en el periodo enero 2009 a diciembre 2019 en el Hospital Central “Dr. Urquinaona”, Maracaibo, Venezuela. Se revisaron los registros clínicos de todas las pacientes sometidas a histerectomía radical y linfadenectomía pélvica bilateral que recibieron quimio-radioterapia concurrente adyuvante con 5-fluorouracilo-cisplatino (grupo de tratamiento) y se compararon con quienes no fueron manejadas con este régimen, las que no recibieron ningún tratamiento adyuvante o solo fueron tratadas con radioterapia (grupo control). Se evaluaron las características generales, efectos adversos del tratamiento, recurrencias de la enfermedad y supervivencia. Resultados: para el análisis final quedaron 164 pacientes, de las cuales 115 (70,1%) fueron del grupo de tratamiento y 49 (29,9%) del control. No se encontraron diferencias estadísticamente significativas en las características clínicas entre ambos grupos (p = ns); sí las hubo en la frecuencia de recurrencias a distancia (p = 0,0056). La supervivencia libre de progresión y la global de ambos grupos no mostraron diferencias significativas (p = 0,2678 y p = 0,3452). Conclusión: no existen beneficios evidentes del uso de 5-fluorouracilo-cisplatino desde el punto de vista de progresión o supervivencia general, en pacientes con carcinoma cuello uterino de alto riesgo.
Palabras clave:
Descargas
Detalles del artículo
Referencias
Galceran J, Ameijide A, Carulla M, Mateos A, Quirós JR, Rojas D, Alemán A, Torrella A, Chico M, Vicente M, Díaz JM, Larrañaga N, Marcos-Gragera R, Sánchez MJ, Perucha J, Franch P, Navarro C, Ardanaz E, Bigorra J, Rodrigo P, Bonet RP; REDECAN Working Group. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017;19(7):799-825. doi: 10.1007/s12094-016-1607-9. DOI: https://doi.org/10.1007/s12094-016-1607-9
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524-548. doi: 10.1001/jamaoncol.2016.5688. DOI: https://doi.org/10.1001/jamaoncol.2016.5688
Kokka F, Bryant A, Brockbank E, Powell M, Oram D. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev. 2015;(4):CD010260. doi: 10.1002/14651858.CD010260.pub2. DOI: https://doi.org/10.1002/14651858.CD010260.pub2
Fregnani JH, de Oliveira Latorre Mdo R, Novik PR, Lopes A, de Oliveira JC, Tsunoda AT, Soares FA. Extent of pelvic lymphadenectomy in women with squamous cell carcinoma of the uterine cervix: is there any prognostic value? J Surg Oncol. 2009;100(3):252-7. doi: 10.1002/jso.21252. DOI: https://doi.org/10.1002/jso.21252
Brambs CE, Höhn AK, Hentschel B, Fischer U, Bilek K, Horn LC. The prognostic impact of grading in FIGO IB and IIB squamous cell cervical carcinomas. Geburtshilfe Frauenheilkd. 2019;79(2):198-204. doi: 10.1055/a-0828-7681. DOI: https://doi.org/10.1055/a-0828-7681
Trudel M, Merlot B, Dedet B, Faye N, Kerdraon O, Vinatier D, Collinet P. Is radical hysterectomy necessary in surgical procedure for early stage cervical cancer? Gynecol Obstet Fertil. 2013;41(12):715-21. doi: 10.1016/j.gyobfe.2013.10.002. DOI: https://doi.org/10.1016/j.gyobfe.2013.10.002
Sakakibara A, Matsui K, Katayama T, Higuchi T, Terakawa K, Konishi I. Age-related survival disparity in stage IB and IIB cervical cancer patients. J Obstet Gynaecol Res. 2019;45(3):686-694. doi: 10.1111/jog.13891. DOI: https://doi.org/10.1111/jog.13891
Liu MT, Hsu JC, Liu WS, Wang AY, Huang WT, Chang TH, Pi CP, Huang CY, Huang CC, Chou PH, Chen TH. Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy. Eur J Cancer Care (Engl). 2008;17(2):174-81. doi: 10.1111/j.1365-2354.2007.00831.x. DOI: https://doi.org/10.1111/j.1365-2354.2007.00831.x
Chen L, Lü WG, Xie X, Chen HZ, Yu H, Ni XH. Analysis of prognostic factors in patients with cervical squamous cell carcinoma of stage Ib and IIa. Zhonghua Fu Chan Ke Za Zhi. 2005;40(4):239-42.
Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, Zaino RJ. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65(1):169-76. DOI: https://doi.org/10.1016/j.ijrobp.2005.10.019
Lee JW, Kim BG, Lee SJ, Lee SH, Park CS, Lee JH, Huh SJ, Bae DS. Preliminary results of consolidation chemotherapy following concurrent chemoradiation after radical surgery in high-risk early-stage carcinoma of the uterine cervix. Clin Oncol (R Coll Radiol). 2005;17(6):412-7. doi: 10.1016/j.clon.2005.02.006 DOI: https://doi.org/10.1016/j.clon.2005.02.006
Sartori E, Tisi G, Chiudinelli F, La Face B, Franzini R, Pecorelli S. Early stage cervical cancer: adjuvant treatment in negative lymph node cases. Gynecol Oncol. 2007;107(1 Suppl 1):S170-4. doi: 10.1016/j.ygyno.2007.07.026 DOI: https://doi.org/10.1016/j.ygyno.2007.07.026
Rushdan MN, Tay EH, Khoo-Tan HS, Lee KM, Low JH, Ho TH, Yam KL. Tailoring the field and indication of adjuvant pelvic radiation for patients with FIGO stage Ib lymph nodes-negative cervical carcinoma following radical surgery based on the GOG score--a pilot study. Ann Acad Med Singapore. 2004;33(4):467-72.
Mabuchi S, Morishige K, Isohashi F, Yoshioka Y, Takeda T, Yamamoto T, Yoshino K, Enomoto T, Inoue T, Kimura T. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors. Gynecol Oncol. 2009;115(3):482-7. doi: 10.1016/j.ygyno.2009.09.002. DOI: https://doi.org/10.1016/j.ygyno.2009.09.002
Reichert ZR, Wahl DR, Morgan MA. Translation of targeted radiation sensitizers into clinical trials. Semin Radiat Oncol. 2016;26(4):261-70. doi: 10.1016/j.semradonc.2016.06.001. DOI: https://doi.org/10.1016/j.semradonc.2016.06.001
Petrelli F, De Stefani A, Raspagliesi F, Lorusso D, Barni S. Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis. Gynecol Oncol. 2014;134(1):166-71. doi: 10.1016/j.ygyno.2014.04.049. DOI: https://doi.org/10.1016/j.ygyno.2014.04.049
Stehman FB, Ali S, Keys HM, Muderspach LI, Chafe WE, Gallup DG, Walker JL, Gersell D. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial. Am J Obstet Gynecol. 2007;197(5):503.e1-6. doi: 10.1016/j.ajog.2007.08.003 DOI: https://doi.org/10.1016/j.ajog.2007.08.003
Cheewakriangkrai C, Srisomboon J, Chitapanarux I, Suprasert P, Phongnarisorn C, Siriaree S, Charoenkwan K. Concurrent cisplatin-based chemoradiation and adjuvant hysterectomy for bulky stage IB-IIA cervical cancer. J Med Assoc Thai. 2005;88(10):1331-7.
Valdes G, Iwamoto KS. Re-evaluation of cellular radiosensitization by 5-fluorouracil: high-dose, pulsed administration is effective and preferable to conventional low-dose, chronic administration. Int J Radiat Biol. 2013;89(10):851-62. doi: 10.3109/09553002.2013.797620. DOI: https://doi.org/10.3109/09553002.2013.797620
Liu JL, Huang WS, Lee KC, Tung SY, Chen CN, Chang SF. Effect of 5-fluorouracil on excision repair cross-complementing 1 expression and consequent cytotoxicity regulation in human gastric cancer cells. J Cell Biochem. 2018;119(10):8472-8480. doi: 10.1002/jcb.27073. DOI: https://doi.org/10.1002/jcb.27073
Matsuo K, Shimada M, Aoki Y, Sakamoto M, Takeshima N, Fujiwara H, Matsumoto T, Mikami M, Sugiyama T. Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation. Int J Cancer. 2017;141(5):1042-1051. doi: 10.1002/ijc.30793. DOI: https://doi.org/10.1002/ijc.30793
Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D, Mutch DG. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22(5):872-80. DOI: https://doi.org/10.1200/JCO.2004.07.197
Datta NR, Stutz E, Liu M, Rogers S, Klingbiel D, Siebenhüner A, Singh S, Bodis S. Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: A systematic review and meta-analysis. Gynecol Oncol. 2017;145(2):374-385. doi: 10.1016/j.ygyno.2017.01.033. DOI: https://doi.org/10.1016/j.ygyno.2017.01.033
Tangjitgamol S, Katanyoo K, Laopaiboon M, Lumbiganon P, Manusirivithaya S, Supawattanabodee B. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer. Cochrane Database Syst Rev. 2014;(12):CD010401. doi: 10.1002/14651858.CD010401.pub2. DOI: https://doi.org/10.1002/14651858.CD010401.pub2
Monk BJ, Wang J, Im S, Stock RJ, Peters WA 3rd, Liu PY, Barrett RJ 2nd, Berek JS, Souhami L, Grigsby PW, Gordon W Jr, Alberts DS; Gynecologic Oncology Group; Southwest Oncology Group; Radiation Therapy Oncology Group. Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol. 2005;96(3):721-8. doi: 10.1016/j.ygyno.2004.11.007 DOI: https://doi.org/10.1016/j.ygyno.2004.11.007
Citado por
